The Company is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug. The Company was established on July 02, 2008.
The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on February 29, 2016.
Headquarters
8F, C Dong, 242, Pangyo-Ro, Bundang-Gu
Seongnam; Gyeonggi;
Postal Code: 13487
Contact Details: Purchase the Qurient Co., Ltd. report to view the information.
Website: http://www.qurient.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service